Is Coronary Revascularization Useful in Renal Transplant Candidates?

Coronary artery disease is the main cause of death in patients with functioning renal transplant, reaching 30%, with the highest rate at peri transplant stage. At the same time, the incidence of acute myocardial infraction (AMI) after renal transplant ranges from 5% to 11%. This is why asymptomatic candidates are routinely screened for CAD before transplant. 

¿Es útil la revascularización coronaria en pacientes candidatos a trasplante renal?

The aim of this meta-analysis was to compare the effectiveness of coronary revascularization vs optimal medical treatment before transplant. 

Primary end point was all cause mortality. 

8 studies were looked at, including 945 patients in total. 35.9% were women, mean age 56. Five studies reported total mortality. 

There were no significant differences (RR 1.16 [95% CI, 0.63-2.12] in primary end point. Four studies reported cardiovascular mortality, also with no significant differences. (RR, 0.75 [95% CI, 0.29–1.89]). 

Read also: Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Finally , 6 studies reported major cardiovascular events with the same result (RR,0.78 [95% CI, 0.30–2.07]).

Conclusion

This meta-analysis showed coronary revascularization is not superior to optimal medical treatment when it comes to reducing total mortality, cardiovascular mortality, and cardiovascular events in renal transplant candidates

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez
Member of the Editorial Board of SOLACI.org

Original Title: Coronary Revascularization Versus Optimal Medical Therapy in Renal Transplant Candidates With Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Reference: Muhammad U. Siddiqui, J Am Heart Assoc. 2022; 11:e023548.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...